Body CompositionGLOWNCT07422987
GLP-1RA Effects on Lean Mass and Bone Health in Midlife Women
An observational study of Body Composition and Muscle Function, run by University of Kansas Medical Center at 1 site in United States.
Trial summary
This study is designed with the interest to learn on the effects of estrogen levels and how it affects body compositions and muscle function in midlife women who are taking a GLP-1RA for weight loss. Read more about this study
- Who is it for?
- Ages 35 to 60 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Body Composition, Muscle Function, GLP-1
- How many people
- 50 participants
- Where
- 1 siteUnited States
- Study dates
- 12 Feb 2026to 30 Jun 2027
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 35 to 60 years
- Women only
- Healthy volunteers accepted
- Adult
Study population: Women in midlife who are establishing care at the KU OBGYN's weight management clinic
Who may be able to join
- Females
- Age 35-60 year
- BMI≥30 or BMI≥27 and at least one cardiometabolic risk factor (dyslipidemia, hypertension, obstructive sleep apnea, metabolic syndrome, fatty liver, PCOS)
- Newly prescribed a GLP-1RA medication
- English speaking
- Body weight stable for the past 6 months
Who cannot join
- Pregnant women
- Under age 35 or over age 60
- Born male
- Cannot consent for themselves
- Cannot read and speak in English
- Type 2 diabetes
Show all 9Show fewer
- Recently discontinued a GLP-1RA medication (less than 6-months since discontinuing)
- Contraindications for taking a GLP-1 RA medication (personal or family history of medullary thyroid carcinoma, personal or family history of multiple endocrine neoplasia type 2, personal history of pancreatitis, pregnancy, hypersensitivity to the drug or any component of the drug, active suicidal ideation)
- Currently taking aromatase inhibitors or selective estrogen receptor modulators (SERMs)
Trial locations and contacts
1 site in 1 country.
United States1 site
The University of Kansas Medical Center
Kansas City, Kansas, 66160
About this study
This study is designed with the interest to learn on the effects of estrogen levels and how it affects body compositions and muscle function in midlife women who are taking a GLP-1RA for weight loss.
- Conditions
- Body Composition, Muscle Function, GLP-1, Estrogen Level
- Keywords
- Midlife, Women's health, Dietary quality
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| GLOW Participants | New patients, those who are newly prescribed a GLP-1RA medication will be invited to participate in the study where different measurements will be completed to assess body composition, hormone levels, muscle strength and nutrition. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Body weight
Assess changes in body weight by measuring weight on a calibrated scale
Measured: Baseline through 6-month visit
Body composition
Assess changes in lean and fat mass and fat-free mass in kilograms by total body DXA scan
Measured: Baseline through 6-month visit
Bone mineral density (BMD)
Assess changes in bone mineral density (BMD) by completing femur DXA scans
Measured: Baseline through 6-month visit
Muscle function
Assess muscle function changes in pounds by completing Grip strength tests
Measured: Baseline through 6-month visit
Muscle function
Assess changes to muscle function by the number of repetitions achieved per 30-second Sit-to-stand test
Measured: Baseline through 6-month visit
Secondary outcomes (4)
Estrogen level role in BMD changes during GLP-1RA therapy
Examine the moderating role of estrogen levels on changes in bone mineral density (BMD) during GLP-1RA therapy.
Measured: Baseline through 6-month visit
Estrogen level role in muscle function changes during GLP-1RA therapy
Examine the moderating role of estrogen levels on changes in muscle function during GLP-1RA therapy.
Measured: Baseline through 6-month visit
Diet intake
Examine changes in dietary intake including protein consumption by collecting 24-hrs diet recalls.
Measured: Baseline through 6-month visit
Diet quality
Examine changes in dietary quality by collecting 24-hrs diet recalls.
Measured: Baseline through 6-month visit
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Feb 2026
- Study start12 Feb 2026
- Primary completion30 Jun 2027 (estimated)
- Study completion30 Jun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Body CompositionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Kansas Medical Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Johanna Finkle, MD, Principal investigator, University of Kansas Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07422987
- Sponsor's protocol ID
- STUDY00161780
- Acronym
- GLOW
- Status last verified
- Aug 2026
- First submitted
- 26 Jan 2026
- Last updated
- 7 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No